AstraZeneca has halted its planned £200m Cambridge research site expansion, leaving its £650m UK investment package stalled.
The project was expected to create 1,000 jobs, but AstraZeneca cited internal reassessments and gave no further details.
In January, the firm abandoned a £450m investment in Merseyside after government support was cut.
The pause contrasts with AstraZeneca’s US pledge to invest $50bn by 2030 in manufacturing and research facilities.
The UK pharmaceutical industry faced further blows this week, with Merck scrapping a £1bn London research centre.
Eli Lilly also paused a £279m gateway lab in London, while Sanofi warned the UK was no longer attractive for investment.
Experts say stalled investments highlight tensions over NHS drug pricing and lack of a competitive life sciences strategy.
Trending
- Secular Iran: How a Post-Theocratic State Could Shift Global Power
- Western Euthanasia Expansion: The Ethical Crisis Deepens
- Spain’s Euthanasia-Immigration Storm: Noelia Castillo Ramos Case
- Southern Africa’s Quiet Turn Westward: Economic Shift Drives New Alliances
- California Honors Genentech 50-Year Legacy
- UConn Wins NCAA Final Four Thriller
- New U.S. Sustainability Rules Guide Firms
- Senate Advances DHS Funding Package
AstraZeneca Pauses £200m Cambridge Expansion Amid UK Pharma Struggles
Andrew Rogers
Andrew Rogers is a freelance journalist based in Chicago, USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He graduated with a degree in Journalism from the University of Florida. Over the years, he has contributed to leading outlets such as The New York Times, CNN, and Reuters. Recognized for his sharp reporting and thoughtful analysis, Andrew delivers accurate and timely news that keeps readers updated on key national and global developments.
Add A Comment